Cyteir Therapeutics Presented Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer

10/12/23 7:36:23 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CYT alert in real time by email

Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination with Capecitabine in Platinum-Resistant Ovarian Cancer" (Poster: LB_A13) at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting in Boston, Massachusetts.

Get the next $CYT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CYT

Date	Price Target	Rating	Analyst
2/7/2022	$16.00	Outperform	Northland Capital
7/13/2021	$40.00	Outperform	Wedbush
7/13/2021	$33.00	Overweight	Morgan Stanley
7/13/2021	$23.00	Buy	B of A Securities
7/13/2021	$30.00	Overweight	JP Morgan

More analyst ratings

$CYT
Press Releases

Fastest customizable press release news feed in the world

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq
Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today announced that it has formally notified The Nasdaq Stock Market ("Nasdaq") of its intent to delist the Company's common stock from the Nasdaq Global Select Market. Cyteir expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") relating to the voluntary delisting of its common stock on or about March 18, 2024 and has requested that the trading of the Common Stock on Nasdaq be suspended effective before the market opens on the same day. Cyteir does not expect that a trading market will develop for its common stock following suspension of trading on Nasdaq. Cyteir intends to
3/7/24 4:30:00 PM ET
$CYT
Biotechnology: Pharmaceutical Preparations
Health Care
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer now active and recruiting patients BT8009 initial clinical data showed a promising response and differentiated safety profile R&D Day outlined near-term strategic priorities and highlighted breadth of Bicycle® platform technology and ability to develop highly differentiated precision therapies for cancer and other diseases Stephen Sands appointed to Board of Directors Cash and cash equivalents of $526.4 million as of December 31, 2023, expected to provide financial runway into 2026 Bi
2/20/24 7:05:00 AM ET
$BCYC
$CYT
Biotechnology: Pharmaceutical Preparations
Health Care
Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile
- CYT-0851 demonstrated activity in combination with capecitabine in heavily pretreated platinum-refractory or -resistant ovarian cancer patients with a generally well tolerated safety profile - Overall disease control rate was 91% in the capecitabine combination with a median progression-free survival of 170 days Cyteir Therapeutics, Inc. ("Cyteir") (NASDAQ:CYT) today presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter (MCT) Inhibitor, in Combination
10/12/23 7:30:00 AM ET
$CYT
Biotechnology: Pharmaceutical Preparations
Health Care

Cyteir Therapeutics Presented Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer

Chat with this insight

Recent Analyst Ratings for $CYT

$CYT Market Insights

Live Market Insights

The Official Delisting Of Cyteir's Common Stock Will Be Effective On Or About March 28, 2024, Ten Days After The Filing Of The Form 25

Cyteir Announces On Or About March 18, 2024 The Trading Of The Common Stock On Nasdaq Be Suspended Effective Before The Market Opens

B of A Securities Downgrades Cyteir Therapeutics to Underperform, Announces $3 Price Target

$CYT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Leonard Braden Michael bought $503,238 worth of shares (170,589 units at $2.95) (SEC Form 4)

Leonard Braden Michael bought $342,469 worth of shares (113,777 units at $3.01) (SEC Form 4)

New insider Leonard Braden Michael claimed ownership of 3,704,687 shares (SEC Form 3)

$CYT SEC Filings

SEC Form 15-12G filed by Cyteir Therapeutics Inc.

SEC Form S-8 POS filed by Cyteir Therapeutics Inc.

SEC Form S-8 POS filed by Cyteir Therapeutics Inc.

$CYT Press Releases

Fastest customizable press release news feed in the world

Cyteir Announces Timeline for Voluntarily Delisting from Nasdaq

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results

Ongoing Results From a Dose Expansion Cohort of CYT-0851 in Combination With Capecitabine in Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity and Generally Well Tolerated Safety Profile

$CYT Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by Cyteir Therapeutics Inc. (Amendment)

SEC Form SC 13D/A filed by Cyteir Therapeutics Inc. (Amendment)

SEC Form SC 13G/A filed by Cyteir Therapeutics Inc. (Amendment)

$CYT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Leonard Braden Michael bought $503,238 worth of shares (170,589 units at $2.95) (SEC Form 4)

Leonard Braden Michael bought $342,469 worth of shares (113,777 units at $3.01) (SEC Form 4)

$CYT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$CYT Financials

Live finance-specific insights

Northland Capital initiated coverage on Cyteir Therapeutics with a new price target

Wedbush initiated coverage on Cyteir Therapeutics with a new price target

Morgan Stanley initiated coverage on Cyteir Therapeutics with a new price target

Cyteir Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Cyteir Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 16, 2022

$CYT Leadership Updates

Live Leadership Updates

Cyteir Therapeutics Names Krisztina Nemenyi as Senior Vice President of Regulatory Affairs and Quality

Recent Analyst Ratings for
$CYT

$CYT
Market Insights

$CYT
Insider Trading

$CYT
SEC Filings

$CYT
Press Releases

$CYT
Large Ownership Changes

$CYT
Insider Purchases

$CYT
Analyst Ratings

$CYT
Financials

$CYT
Leadership Updates